Zurcher Kantonalbank Zurich Cantonalbank Sells 48,781 Shares of Catalent, Inc. (NYSE:CTLT)

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in Catalent, Inc. (NYSE:CTLT) by 58.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 34,681 shares of the company’s stock after selling 48,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Catalent were worth $1,558,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Gladius Capital Management LP bought a new position in shares of Catalent during the 3rd quarter valued at about $28,000. Exchange Traded Concepts LLC bought a new position in shares of Catalent during the 3rd quarter valued at about $31,000. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares during the last quarter. PFG Private Wealth Management LLC bought a new position in shares of Catalent during the 3rd quarter valued at about $155,000. Finally, V Square Quantitative Management LLC bought a new position in shares of Catalent during the 3rd quarter valued at about $181,000.

Catalent Stock Performance

Shares of NYSE:CTLT opened at $55.81 on Friday. The firm has a market cap of $10.10 billion, a PE ratio of -8.21, a price-to-earnings-growth ratio of 6.04 and a beta of 1.20. The firm’s 50 day simple moving average is $56.76 and its 200-day simple moving average is $48.53. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business posted $0.62 earnings per share. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. As a group, equities analysts predict that Catalent, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

CTLT has been the subject of several research reports. UBS Group reissued a “neutral” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Stephens reaffirmed an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Finally, StockNews.com started coverage on shares of Catalent in a research report on Friday, April 19th. They issued a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.